On Friday, Adma Biologics Inc (NASDAQ: ADMA) opened lower -5.75% from the last session, before settling in for the closing price of $21.20. Price fluctuations for ADMA have ranged from $6.84 to $25.67 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
It was noted that within the last five years, the titan of the Healthcare sector saw sales topped by 71.73%. Company’s average yearly earnings per share was noted 31.94% at the time writing. With a float of $230.39 million, this company’s outstanding shares have now reached $238.53 million.
The extent of productivity of a business whose workforce counts for 685 workers is very important to gauge. In terms of profitability, gross margin is 51.4%, operating margin of 32.59%, and the pretax margin is 29.48%.
Adma Biologics Inc (ADMA) Insider Updates
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Adma Biologics Inc is 3.49%, while institutional ownership is 84.15%. The most recent insider transaction that took place on Apr 15 ’25, was worth 450,660. In this transaction President and CEO of this company sold 21,000 shares at a rate of $21.46, taking the stock ownership to the 2,055,850 shares. Before that another transaction happened on Mar 19 ’25, when Company’s President and CEO sold 21,000 for $18.92, making the entire transaction worth $397,320. This insider now owns 2,061,850 shares in total.
Adma Biologics Inc (ADMA) Performance Highlights and Predictions
According to the Wall Street analysts, stocks earnings will be around 31.94% per share during the next fiscal year.
Adma Biologics Inc (NASDAQ: ADMA) Trading Performance Indicators
Check out the current performance indicators for Adma Biologics Inc (ADMA). In the past quarter, the stock posted a quick ratio of 3.36. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 10.38. Likewise, its price to free cash flow for the trailing twelve months is 52.62.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 0.84, a number that is poised to hit 0.15 in the next quarter and is forecasted to reach 0.98 in one year’s time.
Technical Analysis of Adma Biologics Inc (ADMA)
The latest stats from [Adma Biologics Inc, ADMA] show that its last 5-days average volume of 5.59 million was superior to 3.2 million than last year’s volume. As of the previous 9 days, the stock’s Stochastic %D was 35.38%. Additionally, its Average True Range was 1.61.
During the past 100 days, Adma Biologics Inc’s (ADMA) raw stochastic average was set at 53.25%, which indicates a significant increase from 17.77% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 83.89% in the past 14 days, which was higher than the 61.58% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $20.04, while its 200-day Moving Average is $18.15. Now, the first resistance to watch is $21.02. This is followed by the second major resistance level at $22.06. The third major resistance level sits at $22.64. If the price goes on to break the first support level at $19.40, it is likely to go to the next support level at $18.82. Assuming the price breaks the second support level, the third support level stands at $17.78.
Adma Biologics Inc (NASDAQ: ADMA) Key Stats
There are currently 237,615K shares outstanding in the company with a market cap of 4.77 billion. Presently, the company’s annual sales total 426,450 K according to its annual income of 197,670 K. Last quarter, the company’s sales amounted to 117,550 K and its income totaled 111,900 K.
